Literature DB >> 24421803

Pulmonary mucormycosis in a patient with Crohn disease on immunosuppressive medications including infliximab.

Alissa J Wright1, Theodore Steiner1, Ana Maria Bilawich2, John C English3, C Frank Ryan4.   

Abstract

Entities:  

Year:  2013        PMID： 24421803      PMCID： PMC3720000          DOI： 10.1155/2013/363250

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN： 1712-9532            Impact factor:   2.471


× No keyword cloud information.
  8 in total

Review 1.  Infectious complications associated with immunomodulating biologic agents.

Authors:  Sophia Koo; Francisco M Marty; Lindsey R Baden
Journal:  Infect Dis Clin North Am       Date:  2010-06       Impact factor: 5.982

Review 2.  Pharmacokinetic/pharmacodynamic profile of posaconazole.

Authors:  Yanjun Li; Ursula Theuretzbacher; Cornelius J Clancy; M Hong Nguyen; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

Review 3.  Epidemiology and outcome of zygomycosis: a review of 929 reported cases.

Authors:  Maureen M Roden; Theoklis E Zaoutis; Wendy L Buchanan; Tena A Knudsen; Tatyana A Sarkisova; Robert L Schaufele; Michael Sein; Tin Sein; Christine C Chiou; Jaclyn H Chu; Dimitrios P Kontoyiannis; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2005-07-29       Impact factor: 9.079

Review 4.  Mucormycosis: its contemporary face and management strategies.

Authors:  Hsin-Yun Sun; Nina Singh
Journal:  Lancet Infect Dis       Date:  2011-04       Impact factor: 25.071

Review 5.  Zygomycetes in human disease.

Authors:  J A Ribes; C L Vanover-Sams; D J Baker
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

6.  Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

Authors:  H M van Dullemen; S J van Deventer; D W Hommes; H A Bijl; J Jansen; G N Tytgat; J Woody
Journal:  Gastroenterology       Date:  1995-07       Impact factor: 22.682

7.  Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis.

Authors:  Caitlin Reed; Richard Bryant; Ashraf S Ibrahim; John Edwards; Scott G Filler; Robert Goldberg; Brad Spellberg
Journal:  Clin Infect Dis       Date:  2008-08-01       Impact factor: 9.079

8.  Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.

Authors:  Juan J Gómez-Reino; Loreto Carmona; Vicente Rodríguez Valverde; Emilio Martín Mola; Maria Dolores Montero
Journal:  Arthritis Rheum       Date:  2003-08
  8 in total
  5 in total

1.  Successful Treatment of Primary Cutaneous Mucormycosis Complicating Anti-TNF Therapy with a Combination of Surgical Debridement and Oral Posaconazole.

Authors:  Jose F Camargo; Danny Yakoub; Jeong Hee Cho-Vega
Journal:  Mycopathologia       Date:  2015-06-26       Impact factor: 2.574

Review 2.  COVID-19-associated opportunistic infections: a snapshot on the current reports.

Authors:  Amir Abdoli; Shahab Falahi; Azra Kenarkoohi
Journal:  Clin Exp Med       Date:  2021-08-23       Impact factor: 5.057

3.  Behçet's Disease with Bilateral Renal Infarction Due to Mucormycosis.

Authors:  Kumiko Shimoyama; Tomoyuki Niwa; Shogo Furukawa; Naomi Morishita; Yuka Nagakura; Haruka Yonezawa; Masakazu Hatakeyama; Yusuke Okubo; Daisuki Suzuki; Isao Kosugi; Kazuya Shiogama; Noriyoshi Ogawa
Journal:  Intern Med       Date:  2021-09-18       Impact factor: 1.282

4.  Characteristics of pulmonary mucormycosis and predictive risk factors for the outcome.

Authors:  Jun Feng; Xuefeng Sun
Journal:  Infection       Date:  2018-05-10       Impact factor: 3.553

Review 5.  Gastric mucormycosis complicated by a gastropleural fistula: A case report and review of the literature.

Authors:  Tomohisa Uchida; Momoko Okamoto; Keita Fujikawa; Daisuke Yoshikawa; Akinari Mizokami; Tomo Mihara; Akira Kondo; Kazuo Ohba; Kazuhiro Kurohama; Masahiro Nakashima; Ichiro Sekine; Shigeki Nakamura; Yoshitsugu Miyazaki; Atsushi Kawakami
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.